Boehringer Ingelheim drug wins FDA approval to treat fatal lung disorder

Boehringer Ingelheim's Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn't cure IPF but clinical trial results showed it slowed disease progression.

Editor's Pick

Top Story Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF Boehringer Ingelheim's Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn't cure IPF but clinical trial results showed it slowed disease progression. Sponsored Discover how Mayo Clinic Platform_Solutions Studio can accelerate the commercialization of your digital health solution. Presented by Mayo Clinic Platform_Solutions Studio Whether you're ready to build, validate, or deploy your AI solution into clinical workflows, Solutions Studio offers comprehensive technical and business support tailored to your needs. Learn more.

Featured News

Talkspace Acquires Peer Support Platform Wisdo Health Mental health company Talkspace has purchased Wisdo Health, an AI-powered platform for social health and peer support. How Are Healthcare Leaders Tackling Automation Bias? At MedCity News' INVEST Digital Health conference, healthcare experts explored strategies to mitigate automation bias — emphasizing the importance of vendor responsibility, use case-specific governance and clinician engagement. Turning Missed Appointments into Meaningful Member Action Improving no-show rates is not just about perfecting our reminders — it's about redesigning the member experience from the ground up and creating systems that reflect and accommodate the realities of members' lives. White House AI Action Plan: What Healthcare Leaders Must Do Now Healthcare and life sciences are about to face unprecedented AI-driven regulatory changes that will reshape everything from research and development to drug approval submissions. Here are 10 steps healthcare and life sciences organizations should take to strategically prepare.

Video   Beyond Traditional, Broken Health Models Daniel Karlin, chief medical officer of MindMed, spoke at DiMe's Healthcare 2030 Summit in Washington, D.C. His company is developing novel treatments for brain health disorders, with a focus on psychiatry, neurology and addiction. Karlin urged healthcare leaders to look beyond existing data and assumptions to create more meaningful, systemic improvements.

Sponsored The Top-Rated Assistive Devices for Children With Sensory Processing Disorders Presented by Enabling Devices The best assistive devices for children with sensory processing disorders are those that meet their needs. They will enhance their ability to participate more fully in daily activities. Learn More.

Resources

MedCity FemFwd: How Evvy Is Advancing Women's Health Research In this episode, we're joined by Priyanka Jain, CEO and co-founder of Evvy, a vaginal health company. Jain discusses how Evvy is trying to improve women's health research and what she hopes to achieve as a founding member of the Milken Institute's Women's Health Network. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe